Manchester Peptides catalogue profile
BPC-157 + TB-500
A catalogue combination of two distinct experimental materials discussed in preclinical tissue-repair research. Studies consider cell migration, inflammatory signalling and wound-repair pathways, but the combined ‘Wolverine’ format is not an approved clinical formulation.
Available catalogue formats
Choose the listed format
Prices shown are the current catalogue guide prices.Vial set · Wolverine
BPC-157 + TB-500
Product information
A catalogue combination of two distinct experimental materials discussed in preclinical tissue-repair research. Studies consider cell migration, inflammatory signalling and wound-repair pathways, but the combined ‘Wolverine’ format is not an approved clinical formulation.
Evidence and sources at a glance
- Human evidence
- Robust, replicated controlled human evidence for BPC-157 is absent, and the marketed blend itself lacks an established clinical evidence base.
- Regulatory context
- The combined product is not an approved UK medicine and should not be described as a proven injury treatment.
- BPC-157 systematic review ↗Peer-reviewed overview of evidence and translational limitations.
- PubMed thymosin beta-4 literature ↗Indexed research on thymosin beta-4 biology; not proof of a particular TB-500 product.
Pen · 10 mg + 10 mg
BPC-157 + TB-500
Product information
A catalogue combination of two distinct experimental materials discussed in preclinical tissue-repair research. Studies consider cell migration, inflammatory signalling and wound-repair pathways, but the combined ‘Wolverine’ format is not an approved clinical formulation.
Evidence and sources at a glance
- Human evidence
- Robust, replicated controlled human evidence for BPC-157 is absent, and the marketed blend itself lacks an established clinical evidence base.
- Regulatory context
- The combined product is not an approved UK medicine and should not be described as a proven injury treatment.
- BPC-157 systematic review ↗Peer-reviewed overview of evidence and translational limitations.
- PubMed thymosin beta-4 literature ↗Indexed research on thymosin beta-4 biology; not proof of a particular TB-500 product.
View supplied reference photograph
Plain-English identity
What is BPC-157 + TB-500?
The two are discussed around cell migration, blood-vessel formation, inflammation, collagen organisation and repair signalling in muscle, tendon, ligament, skin and other tissues.
The evidence bases for the two materials are not interchangeable. BPC-157 lacks robust controlled human trials, while thymosin beta-4 has separate research history. The combined 'Wolverine' format is not an approved clinical formulation.
Evidence and sources at a glance
- Human evidence
- Robust, replicated controlled human evidence for BPC-157 is absent, and the marketed blend itself lacks an established clinical evidence base.
- Regulatory context
- The combined product is not an approved UK medicine and should not be described as a proven injury treatment.
- BPC-157 systematic review ↗Peer-reviewed overview of evidence and translational limitations.
- PubMed thymosin beta-4 literature ↗Indexed research on thymosin beta-4 biology; not proof of a particular TB-500 product.
Third-party documentation
Certificates of Analysis
Reference reports concern the named submitted samples. A catalogue batch match has not been established; check the strength and source on each report.Evidence-led research guide
Go deeper into BPC-157 + TB-500
A catalogue combination of two separate experimental materials commonly discussed in tissue-repair research.
Last reviewed 10 October 2026. Research and reference information only. This page does not provide dosing instructions, treatment recommendations or medical advice. Not for human or veterinary consumption.